1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Taking Control Of Our Destiny: Biocon Biologics CEO Tambe Celebrates European Viatris Integration

Fresh Opportunities Loom, With Seven Biosimilars Already In Europe And Three On The Way

 
• By Dave Wallace

With Biocon Biologics having previously integrated its acquisition of Viatris’s biosimilars business in emerging markets and North America, the firm has now completed integration in Europe. In an exclusive interview, CEO Shreehas Tambe tells Generics Bulletin what this means for the company and reveals the opportunities it perceives ahead.

Shreehas Tambe, Biocon Biologics CEO
Shreehas Tambe says that with the European integration, Biocon Biologics is gaining control over its destiny • Source: Biocon Biologics

“Unless you control the business directly, you do not have control over your destiny. That was very clear to us from the beginning.”

This is how Biocon Biologics CEO and managing director Shreehas Tambe describes the significance of the Indian firm’s $3bn acquisition of the biosimilars business of former partner Viatris, a deal which has now completed

Key takeaways:

  • Biocon Biologics has now completed integration of the Viatris biosimilars business in Europe.

  • The firm has seven biosimilars approved and marketed in Europe, with three further products on the way

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By Dave Wallace

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing

 
• By Urtė Fultinavičiūtė

Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.

‘I’ll Be Happy When We Have 40-Plus Assets’ – Sandoz Builds Up Biosimilars

 
• By Dave Wallace

With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.

Fresenius Kabi Lauds Tocilizumab Momentum As ‘Intense’ Transfer To mAbxience Continues

 
• By Dean Rudge

Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.

More from Products

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing

 
• By Urtė Fultinavičiūtė

Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.

‘I’ll Be Happy When We Have 40-Plus Assets’ – Sandoz Builds Up Biosimilars

 
• By Dave Wallace

With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.